Profile data is unavailable for this security.
About the company
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
- Revenue in HKD (TTM)3.08bn
- Net income in HKD655.72m
- Incorporated2020
- Employees1.50k
- LocationWuXi XDC Cayman IncNo. 11 Xinhui Ring Road, Xinwu DistrictWUXI KY1-1104ChinaCHN
- Websitehttps://wuxixdc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Henlius Biotech Inc | 6.22bn | 763.57m | 12.53bn | 3.55k | 16.45 | 4.41 | 10.70 | 2.01 | 1.40 | 1.40 | 11.40 | 5.23 | 0.5764 | 1.90 | 6.82 | 1,710,433.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 6.86 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| 3SBio Inc | 9.29bn | 1.83bn | 13.65bn | 5.61k | 7.59 | 0.8539 | 6.02 | 1.47 | 0.7509 | 0.7509 | 3.81 | 6.68 | 0.3575 | 1.52 | 6.73 | 1,716,495.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 23.87 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 15.37bn | 10.78k | 6.29 | 0.9778 | 5.34 | 1.45 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 3.21 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Simcere Pharmaceutical Group Ltd | 6.99bn | -1.22bn | 15.79bn | 7.03k | -- | 2.15 | -- | 2.26 | -0.4648 | -0.4648 | 2.72 | 2.91 | 0.5198 | 2.19 | 2.64 | 995,369.40 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4709 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.45bn | 3.21bn | 15.83bn | 15.00k | 4.93 | 1.06 | 4.13 | 1.02 | 1.77 | 1.77 | 8.50 | 8.21 | 0.6578 | 3.30 | 3.54 | 1,030,028.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Zai Lab Ltd | 2.52bn | -2.33bn | 16.40bn | 2.18k | -- | 2.94 | -- | 6.52 | -2.39 | -2.39 | 2.59 | 5.59 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| China Medical System Holdings Ltd | 7.74bn | 1.53bn | 19.08bn | 5.78k | 12.46 | 1.08 | 10.73 | 2.47 | 0.6276 | 0.6276 | 3.16 | 7.26 | 0.384 | 2.89 | 5.65 | 1,356,928.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| China Traditional Chinese Med Hldg CoLtd | 18.97bn | 1.01bn | 21.91bn | 17.30k | 21.65 | 0.9294 | 9.49 | 1.15 | 0.2009 | 0.2009 | 3.77 | 4.68 | 0.453 | 1.54 | 1.76 | 1,096,593.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 6.63 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| HUTCHMED (China) Ltd | 4.76bn | -327.14m | 23.70bn | 1.97k | -- | 4.11 | -- | 4.98 | -0.3893 | -0.3893 | 5.52 | 6.62 | 0.4775 | 7.10 | 4.15 | 2,394,864.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| WuXi XDC Cayman Inc | 3.08bn | 655.72m | 24.22bn | 1.50k | 37.47 | 3.66 | 32.21 | 7.86 | 0.539 | 0.539 | 2.73 | 5.51 | 0.5586 | 21.31 | 2.62 | 2,617,298.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | 204.82 | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Resources Pharmaceutical Group Ltd | 276.33bn | 4.16bn | 31.29bn | 72.76k | 7.51 | 0.5865 | 2.45 | 0.1132 | 0.6627 | 0.6627 | 43.98 | 8.49 | 0.966 | 6.09 | 3.00 | 3,786,016.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
Data as of Sep 20 2024. Currency figures normalised to WuXi XDC Cayman Inc's reporting currency: Hong Kong Dollar HKD
8.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Advisers, Inc.as of 16 Nov 2023 | 37.97m | 3.17% |
| UBS Asset Management (Singapore) Ltd.as of 16 Nov 2023 | 15.19m | 1.27% |
| UBS Asset Management (Hong Kong) Ltd.as of 31 Jul 2024 | 15.09m | 1.26% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 9.79m | 0.82% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 7.75m | 0.65% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Jul 2024 | 5.35m | 0.45% |
| Fidelity Management & Research Co. LLCas of 31 Jul 2024 | 4.94m | 0.41% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.41m | 0.20% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 1.18m | 0.10% |
| Harvest Global Investments Ltd.as of 31 Dec 2023 | 939.40k | 0.08% |
More ▼
Data from 31 Dec 2023 - 06 Sep 2024Source: FactSet Research Systems Inc.
